Trial Profile
A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Hydroxycarbamide (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Acronyms CYTO-PV
- 08 Dec 2012 Study presented at the 54th Annual Meeting of the American Society of Hematology (ASH - Abstract #4), according to a media release from the American Society of Hematology.
- 08 Dec 2012 Results published in the New England Journal of Medicine.
- 30 Jul 2012 New trial record